Phase II trial of IMGN 529 in patients with chronic lymphocytic leukaemia

Trial Profile

Phase II trial of IMGN 529 in patients with chronic lymphocytic leukaemia

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2015

At a glance

  • Drugs DEBIO 1562 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2015 New trial record
    • 11 Jan 2015 This study is expected to be initiated in the third quarter of 2015, according to an ImmunoGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top